Abstract: OBJECTIVE We challenge epidemiologic knowledge regarding ovarian carcinoma (OC) by bridging the gap between clinical and autopsy data. METHODS Autopsy reports, histological slides and clinical files from 660 patients in whom OC was diagnosed from 1975-2005 were studied (autopsy cohort, n=233; Clinical Cancer Registry from the local gyneco-oncologic center, n=427). RESULTS Out of the autopsy cohort, we identified four distinct subgroups of patients: 1) OC was diagnosed before autopsy, n=156 (67.0%). 2) OC was an incidental finding, n=16 (6.8%).
almost doubled the percentage of oldest patients (≥80 years at diagnosis) from 4.9% to 9.3% 48 (p=0.013).
49
Conclusions: Epidemiological data from the 1970s-1990s may overestimate true incidence 50 because up to 10% of carcinomas in the ovary were not properly classified. Patients who were 51 first diagnosed with OC by autopsy comprise a distinct subgroup. These are patients who have 52 not been seen by specialized oncologists and thus play no role in their perception of the disease. 53 Nevertheless, these cases have impact on prevalence and incidence data of OC and in an era of 54 reduced autopsy rates will probably be overlooked.
Introduction

59
In developed countries, ovarian carcinoma (OC) is the fifth most frequent cause of cancer death 60 in women and the most lethal gynecologic malignancy [1] . In most cases, the disease is 61 diagnosed in its late stage. Despite current multimodal therapies, most patients cannot be cured. 62 According to WHO estimates in 2012, there are approximately 239,000 new cases annually 63 worldwide, and about 152,000 patients die of the disease [2] . 64 The epidemiologic knowledge regarding the incidence of OC stems predominantly from 65 epidemiological, population-based cancer registries whose aim is to identify all cases from a 66 well-defined regional population, including clinically symptomatic cases as well as autopsy- 
Results
113
Out of the entire autopsy cohort of 233 cases, we identified four distinct subgroups (Table 1) In these cases, which had been autopsied between 1975 and 1997, metastatic disease found 133 during autopsy could be attributed to other primary tumors, and the site of the primaries 134 could be identified retrospectively (colon, n=10; pancreas, n=5; stomach, n=2; extrahepatic 135 bile ducts, n=1; cervix uteri, n=3; corpus uteri, n=1; breast, n=1; kidney, n=1). CDX2, CK7, 136 CK20 and estrogen receptor were the most effective antibodies for discriminating primary 137 OC from metastases to the ovary. 138 The median age of patients with ovarian metastases was 71 years (range: 47-88 years). In 139 12 of these cases, the patients died from tumor of unknown origin and the misinterpretation 140 as "ovarian carcinoma" was made at autopsy. In 12 cases, the patient were wrongly 141 diagnosed with OC while alive and were subsequently treated for this incorrect diagnosis. Table 2 demonstrates the OC incidence data reported by the local gyneco-oncologic center. In order to provide an adjusted "real" OC incidence, we believe that these autopsy cases which the disease is firstly diagnosed at autopsy will decrease. Secondly, autopsy rates have 226 dramatically decreased in many countries [21] [22] [23] [24] . This is also reflected in our autopsy 227 cohort. From the first decade of the study period (1975) (1976) (1977) (1978) (1979) (1980) (1981) (1982) (1983) (1984) Included were six cases which were diagnosed and treated at the Basel gyneco-oncologic center during 319 this period; however, current pathological review showed that they were not primary OC, but rather 320 metastases to the ovaries from other primaries.
321
2 The above mentioned six cases were excluded from the adjusted incidence model.
322
3 From the entire autopsy cohort (n=37), we excluded those four patients who died at the gyneco-oncologic center.
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